The Trump administration is getting some backlash from pharmaceutical companies after it revealed a new plan to pay for some drugs in Medicare based on global prices, according to a STAT report.
PhRMA said the proposal amounted to “price controls” and that it was “disappointed the administration put the needs of patients aside with these proposals,” while Health and Human Services Secretary Alex Azar said pharma’s high drug prices are the “greatest possible barriers to patient access.”
The proposal would reportedly cut back on reimbursement for physician-administered drugs until the U.S. reports paying 126 percent of what certain other countries pay.
According to the report, the administration looks to launch a pilot for half of the country some time in late 2019 or early 2020. The administration, if the pilot produces favorable results, will expand to the rest of the country.